Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 75

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 75
---
 versus performance table. The charts and descriptions below explain the relationship between the columns presented in the pay versus performance table. AbbVie TSR versus Peer Group TSR The graph below shows AbbVie’s cumulative TSR over the five-year period ending with December 31, 2024 as compared to the NYSE Arca Pharmaceutical Index. AbbVie’s cumulative TSR outperformed our peer group during the five years presented in the table. Additionally, AbbVie is committed to a robust return of capital to stockholders with an increase of 235% in its quarterly dividend since 2014 as part of a balanced and disciplined capital allocation program, contributing to our strong cumulative TSR. Comparison of “Compensation Actually Paid” to TSR The chart below demonstrates that the “compensation actually paid” amounts shown for Mr. Michael (for 2024) and Mr. Gonzalez (for 2020-2024) and average “compensation actually paid” to the other NEOs (see footnote (c) to the pay versus performance table) is aligned with AbbVie’s cumulative TSR over the five years presented in the table. The alignment of compensation actually paid with AbbVie’s cumulative TSR over the period presented reflects that a significant portion of the compensation actually paid to Mr. Michael and Mr. Gonzalez, as 2025 Proxy Statement |67

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

applicable, and to the other NEOs is comprised of equity awards. Moreover, AbbVie’s executive compensation philosophy and design is fundamentally based on a commitment to align pay and performance. Comparison of “Compensation Actually Paid” to Net Income AbbVie’s net income was approximately $4.6 billion in 2020, $11.5 billion in 2021, $11.8 billion in 2022, $4.9 billion in 2023 and $4.3 billion in 2024. Mr. Michael’s “compensation actually paid” was approximately $33 million in 2024. Mr. Gonzalez’s “compensation actually paid” was approximately $47 million, $66 million, $67 million, $35 million and $68 million in the corresponding years. The average “compensation actually paid” to AbbVie’s other NEOs (see footnote (c) to the pay versus performance table) was approximately $23 million, $24 million, $20 million, $12 million and $20 million in the corresponding years. Comparison of “Compensation Actually